Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 4:45 PM
Ignite Modification Date:
2025-12-24 @ 4:45 PM
NCT ID:
NCT07036250
Brief Summary:
This is a single-arm, open-label clinical study to evaluate the safety, tolerability, and efficacy of U32 injection in patients with acute myeloid leukemia.
Detailed Description:
The primary objective of this study is to evaluate the safety and tolerability of U32 in the treatment of acute myeloid leukemia and to determine the safe and effective dosage.
Study:
NCT07036250
Study Brief:
Protocol Section:
NCT07036250